Print Page | Sign In | Join
News & Press: Industry Events

QOL Medical Unveiling an Innovative Disease Awareness-Raising Tool at the 2016 World Congress of Ped

Friday, August 26, 2016   (0 Comments)
Share |

QOL Medical Unveiling an Innovative Disease Awareness-Raising Tool at the 2016 World Congress of Pediatric Gastroenterology, Hepatology and Nutrition

VERO BEACH, Fla., Aug. 26, 2016 /PRNewswire/ -- QOL Medical, LLC announced today they will introduce a ground breaking hyper-targeted marketing tool at the 5th Annual World Congress of Pediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN), from October 5th-8th 2016 in Montreal, Canada. World Congress is the largest gathering of pediatric gastroenterologists, hepatologists, research scientists and physician nutritionists. It is designed to promote awareness of the rare disease genetic sucrase isomaltase deficiency (GSID).

QOL's Branded Biodegradable Toilet Seat Wraps

QOL's target audience is the physicians and medical professionals who treat GI (stomach) diseases and conditions but who might not be aware of GSID. So what ad placement would be more appropriate than on a toilet seat? "In this world where people are bombarded with ads, it's crucial to create a way to stand out," said QOL's Vice President of Marketing, Anthony D'Elia. "Our team designed disease state-branded biodegradable toilet seat wraps to place in all of the conference attendees hotel rooms."

(See attached images of toilet seat wraps)

This new hyper-targeted approach will assist in raising rare disease state awareness direct to the physicians. "Increasing rare disease state awareness is imperative to both the medical community and general public."

About Rare Diseases

One in ten Americans has a rare disease, approximately 30 million people, with more than half being children. According to the National Institutes of Health (NIH), a disease is considered rare if it has a prevalence of fewer than 200,000 affected individuals in the United States. There are roughly 7,000 rare diseases currently identified.  

About GSID

Genetic Sucrase-Isomaltase Deficiency/Congenital Sucrase-Isomaltase Deficiency is a rare disorder that affects a person's ability to digest certain sugars due to absent or low levels of two digestive enzymes, sucrase and isomaltase. Sucrase and isomaltase are involved in the digestion of sugar and starch. Sucrase is an enzyme produced in the small intestine that aids in the breakdown of sucrose (table sugar) into glucose and fructose, which are used by the body as fuel. Isomaltase is one of several enzymes that helps digest starches. Failure to absorb dietary sucrose and starch may impact the absorption of other nutrients and the hormonal regulation of gastrointestinal function. Patients with Genetic Sucrase-Isomaltase Deficiency are at risk for chronic malnutrition; indeed, failure to thrive is one of the characteristics of the disease state. In addition to diarrhea, some patients suffer from gassiness, abdominal distention, and pain.

About QOL Medical, LLC

QOL Medical is a specialty biopharmaceutical company dedicated to improving the quality of life for patients with rare diseases, for their families, and for the physicians and caregivers who support them. QOL Medical is a patient-centric company founded in 2003 to focus on the acquisition and commercialization of orphan products in underserved markets. QOL Medical ensures an expanded clinical awareness and patient access for improved quality of life in the treatment of rare and orphan diseases. QOL Medical, in its commitment to assuring safe and effective products for our customers, uses validated procedures through audited and approved vendors for manufacturing, testing, and distribution. Learn more at

Media Contact, QOL Medical, LLC

Tiffany Carter, 818-720-8557 Email

Corporate Contact:
QOL Medical, LLC
3405 Ocean Drive
Vero Beach, FL 32963

Phone: 866-469-3773
Fax: 772-365-3375

QOL Medical, LLC corporate logo


Photo - 
Logo -

To view the original version on PR Newswire, visit:


About BioFlorida

BioFlorida represents nearly 6,000 establishments and research organizations in the biopharmaceutical, medical technology and bioagriculture sectors that collectively employ nearly 83,000 Floridians.


Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.


Email us for a regional Chapter sponsorship.